Over the past decades, eukaryotic Hsp90 has emerged as a crucial target for cancer therapy (Lacey and Lacey, 2021) and the treatment of fungal infections (Li et al., 2022; Yin et al., 2022), resulting in numerous ongoing clinical trials evaluating Hsp90 inhibitors (Graner, 2021; Marcyk et al., 2021; Li and Luo, 2022). The gene discussed is HSP90AB1; the disease is fungal infectious disease.